Evidence map›Paper›PMID 38170977›Full record

ArticleMicrobiology spectrum2024

Comparative reassessment of AcrB efflux inhibitors reveals differential impact of specific pump mutations on the activity of potent compounds.

Sabine Schuster, Martina Vavra, Dave A N Wirth, Winfried V Kern

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Efflux-Mediated Resistance inAntibiotics (Basel, Switzerland) · 2025
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sabine SchusterDivision of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Freiburg, Germany.ORCID 0000-0002-8817-6224
Martina VavraDivision of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Freiburg, Germany.
Dave A N WirthDivision of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Freiburg, Germany.
Winfried V KernDivision of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Freiburg, Germany.

Funding

ShEEP Equipment Request for Magventure X100 fMRI-TMS SystemIS1BX003135 · VA · VETERANS HEALTH ADMINISTRATION · PI MCGREGOR, KEITH MATTHEW · 2015 to 2015
–
BLRD VA IS1 BX003135
6 · The paper itself

Abstract

Multidrug resistance poses global challenges, particularly with regard to Gram-negative bacterial infections. In view of the lack of new antibiotics, drug enhancers, such as efflux pump inhibitors (EPIs), have increasingly come into focus. A number of chemically diverse agents have been reported to inhibit AcrB, the main multidrug transporter in

Indexed as

Escherichia coliEscherichia coli ProteinsAnti-Bacterial AgentsATP-Binding Cassette, Sub-Family C ProteinsDrug Resistance, Multiple, BacterialMicrobial Sensitivity TestsMutationAcrB protein, E coliAnti-Bacterial AgentsATP-Binding Cassette, Sub-Family C ProteinsEscherichia coli ProteinsAcrBefflux pump inhibitormultidrug resistanceRND-type transporter

Identifiers

PMID38170977
PMCPMC10846202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.